A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens.

Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1607-8454 (Electronic) Linking ISSN: 10245332 NLM ISO Abbreviation: Hematology Subsets: MEDLINE

Publication: 2016- : Abingdon : Taylor & Francis
Original Publication: [Amsterdam] : Newark, NJ : Harwood Academic Publishers ; International Publishers Distributor,

Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics ; Hematopoietic Stem Cell Transplantation*; Adult ; Humans ; Imatinib Mesylate/therapeutic use ; Philadelphia Chromosome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Protein Kinase Inhibitors/therapeutic use

Philadelphia chromosome-positive acute lymphoblastic leukemia (PH + ALL) is the most common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis. Previously, the only curative treatment option in PH + ALL was allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Since 2000, targeted therapy combined with chemotherapy, represented by the tyrosine kinase inhibitor Imatinib, has become the first-line treatment for PH + ALL. Currently, the remission rate and survival rate of Imatinib are superior to those of simple chemotherapy, and it can also improve the efficacy of transplantation. More recently, some innovative immune-targeted therapy greatly improved the prognosis of PH + ALL, such as Blinatumomab and Inotuzumab Ozogamicin. For patients with ABL1 mutations and those who have relapsed or are refractory to other treatments, targeted oral small molecule drugs, monoclonal antibodies, Bispecific T cell Engagers (BiTE), and chimeric antigen receptor (CAR) T cells immunotherapy are emerging as potential treatment options. These new therapeutic interventions are changing the treatment landscape for PH + ALL. In summary, this review discusses the current advancements in targeted therapeutic agents shift in the treatment strategy of PH + ALL towards using more tolerable chemotherapy-free induction and consolidation regimens confers better disease outcomes and might obviate the need for HSCT.

Keywords: BCR-ABL1; Philadelphia chromosome; acute lymphoblastic leukemia; immunotherapy; tyrosine kinase inhibitors

8A1O1M485B (Imatinib Mesylate)
0 (Protein Kinase Inhibitors)

Date Created: 20240406 Date Completed: 20240408 Latest Revision: 20240408

20250114

10.1080/16078454.2024.2335856

38581291